Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma. Investigational New Drugs 2003, 21: 341-345. PMID: 14578682, DOI: 10.1023/a:1025472712456.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAdvanced renal cell carcinomaPhase II trialII trialCell carcinomaMemorial Sloan Kettering Cancer Center databaseMetastatic renal cell carcinomaCancer Center databaseProgression of diseaseMonths of startEvaluable patientsMedian TTPPartial responseCell patientsDisease progressionPatientsTreatment efficacyCenter databaseZD1839Antitumor activityProgressionTrialsMonthsFurther studiesCarcinoma